Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1967 5
1975 1
1978 1
1979 3
1981 1
1983 1
1984 3
1985 6
1986 5
1987 12
1988 10
1989 7
1990 14
1991 8
1992 11
1993 17
1994 14
1995 17
1996 18
1997 11
1998 6
1999 10
2000 14
2001 15
2002 6
2003 8
2004 3
2005 8
2006 3
2007 5
2008 4
2009 7
2010 5
2011 8
2012 7
2013 4
2014 7
2015 7
2016 6
2017 8
2018 7
2019 8
2020 7
2021 7
2022 5
2023 2
2024 8
2025 9
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

346 results

Results by year

Filters applied: . Clear all
Page 1
Multi-specialty recommendations for the appropriate and affordable lower limb vein-lymphatic disorders management.
Gianesini S, Danese M, Pagano M, Allegra C, Alqedrah D, Avruscio G, Azzolina D, Cappello E, Doganci S, Farina M, Gaddi A, Gianaroli L, Hussein E, Lazarashvili Z, Lobo Lima JP, Maghetti A, Malchiodi G, Martini R, Mattaliano V, Mo M, Moretti AM, Mosti G, Noce F, Portugal M, Rial R, Rockson S, Romanelli M, Saggini R, Stoughton J, Tessitore A, Vagnoni E, Vitale M, Chi YW. Gianesini S, et al. Among authors: allegra c. Int Angiol. 2026 Feb;45(1):1-64. doi: 10.23736/S0392-9590.25.05536-1. Int Angiol. 2026. PMID: 41670291 Free article. No abstract available.
Erratum: Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer.
Chen L, Wang Y, Cai C, Ding Y, Kim RS, Lipchik C, Gavin PG, Yothers G, Allegra CJ, Petrelli NJ, Suga JM, Hopkins JO, Saito NG, Evans T, Jujjavarapu S, Wolmark N, Lucas PC, Paik S, Sun M, Pogue-Geile KL, Lu X. Chen L, et al. Among authors: allegra cj. J Clin Oncol. 2025 Nov;43(31):3427. doi: 10.1200/JCO-25-02281. Epub 2025 Oct 2. J Clin Oncol. 2025. PMID: 41037767 No abstract available.
NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with "quadruple wild-type" (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated.
Freeman TJ, George TJ, Jacobs SA, Yothers G, Kolevska T, Feng H, Lipchik C, Maley S, Song N, Srinivasan A, Finnigan M, Wade JL 3rd, Buchschacher GL Jr, Al Baghdadi T, Shipstone A, Lin D, Puhalla SL, Allegra CJ, Wolmark N, Pogue-Geile KL. Freeman TJ, et al. Among authors: allegra cj. Cancer Chemother Pharmacol. 2025 Aug 9;95(1):80. doi: 10.1007/s00280-025-04802-8. Cancer Chemother Pharmacol. 2025. PMID: 40782152 Clinical Trial.
p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2+ breast cancer that limits trastuzumab deruxtecan efficacy.
Hu D, Lyu X, Li Z, Ekambaram P, Dongre A, Freeman T, Joy M, Atkinson JM, Brown DD, Cai Z, Carleton NM, Crentsil HE, Little J 4th, Kemp F, Klei LR, Beecher M, Sperinde J, Huang W, Joensuu H, Srinivasan A, Pogue-Geile KL, Wang Y, Feng H, Eli LD, Lalani AS, Zou J, Tseng GC, Bruno TC, Lee AV, Oesterreich S, Wolmark N, Allegra CJ, Jacobs SA, McAllister-Lucas LM, Lucas PC. Hu D, et al. Among authors: allegra cj. Nat Cancer. 2025 Jul;6(7):1202-1222. doi: 10.1038/s43018-025-00969-4. Epub 2025 Jun 27. Nat Cancer. 2025. PMID: 40579589
Erratum: Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms.
George TJ, Lee JH, DeRemer DL, Hosein PJ, Staal S, Markham MJ, Jones D, Daily KC, Chatzkel JA, Ramnaraign BH, Close JL, Ezenwajiaku N, Murphy MC, Allegra CJ, Rogers S, Zhang Z, Li D, Srinivasan G, Shaheen M, Hromas R. George TJ, et al. Among authors: allegra cj. JCO Precis Oncol. 2025 May;9:e2500369. doi: 10.1200/PO-25-00369. Epub 2025 May 22. JCO Precis Oncol. 2025. PMID: 40403212 Free PMC article. No abstract available.
Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group.
Rajdev L, King GG, Lieu CH, Cohen SA, Pant S, Uboha NV, Deming D, Malla M, Kasi A, Klute K, Spencer KR, Dasari A, Morris VK, Botta G, Lowy AM, O'Hara MH, Eads J, King D, Shah MA, Hong TS, Parikh A, Klempner SJ, Jabbour SK, Chawla A, Molena D, George TJ, Gibson MK, Allegra C, Goodman K, Eng C, Philip PA. Rajdev L, et al. Among authors: allegra c. JCO Precis Oncol. 2025 Mar;9:e2400489. doi: 10.1200/PO-24-00489. Epub 2025 Mar 6. JCO Precis Oncol. 2025. PMID: 40048671 Free PMC article.
Prevalence of Duchenne muscular dystrophy in Italy: a nationwide survey.
Capasso A, Cicala G, Ricci M, Pane M, D'Amico A, Bruno C, Sansone VA, Messina S, Bello L, Pegoraro E, D'Angelo MG, Masson R, Berardinelli A, Pini A, Ricci F, Mongini TE, Coccia M, Nigro V, Trabacca A, Filosto M, Comi G, Magri F, Barp A, Battini R, Previtali SC, Valentino ML, Diella E, Dosi C, Ruggiero L, Siciliano G, Ricci G, Catteruccia M, Arpaia C, Coratti G, Norcia G, Bonanno S, Verriello L, Agosto C, Varone A, Ferlini A, Maioli MA, Brogna C, Siliquini S, Bruno I, Panicucci C, Allegra C, Albamonte E, Mercuri E; Italian DMD group. Capasso A, et al. Among authors: allegra c. Eur J Pediatr. 2024 Dec 16;184(1):86. doi: 10.1007/s00431-024-05903-x. Eur J Pediatr. 2024. PMID: 39680193
346 results